Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARYA-1: ET140203 T Cells in Advanced HCC
NCT04502082Phase 1Terminated
- Sponsor
- Eureka Therapeutics, Inc.
- Start
- Apr 2021
- Primary completion
- Aug 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ET140203 in hepatocellular carcinoma (HCC), sponsored by Eureka Therapeutics, Inc. Primary endpoints: Incidence rates of adverse events at 28 days, Severity rates of adverse events at 28 days and 2 more. Started Apr 2021; status: terminated.
02
Drugs
ET140203
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04502082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04502082.